<div><div></div><div><span><p><span>David Krempa, an officer serving as Chief Business Officer, filed a Form 4 reporting sales of Eton Pharmaceuticals common stock. The transactions were executed at weighted-average prices ranging roughly from $31.47 to $33.88 per share as reported and in multiple trades at specified price ranges. The total proceeds from the five sales reported on May 22, May 26 and May 27, 2026 amounted to $3,229,923. After these transactions, Krempa directly beneficially owns 25,249 shares of common stock. The reporting person authorized a designated filer to submit this Form 4 on his behalf.</span></p><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Krempa David</span></td></tr><tr><td><span>Relationship</span></td><td><span>Chief Business Officer</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$3,229,923</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ETON

SBIO

<p>David Krempa, Chief Business Officer of Eton Pharmaceuticals, sold shares worth $3.2 million, with transactions executed at prices between $31.47 and $33.88 per share. The sales occurred on May 22, 26, and 27, 2026, totaling $3,229,923. Post-sale, Krempa retains 25,249 shares of common stock.</p>

TradingView

Eton Pharmaceuticals

iShares Biotechnology ETF

Health Care Select Sector SPDR

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares US Pharma

Eton Pharmaceuticals Chief Business Officer Sold Shares Worth Over $3.2M